Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rossi

Showing results (591-600 of 724) with videos related to

Pageof 73
Sort By:
Ecology and Evolution|July 25, 2018
Rivers shape population genetic structure in <i>Mauritia flexuosa</i> (Arecaceae)Nilo L Sander, Francisco Pérez-Zavala, Carolina J Da Silva, et al.
The British Journal of Dermatology|December 4, 2023
Burden of atopic dermatitis in paediatric patients: an international cross-sectional studyStephan Weidinger, Eric L Simpson, Jonathan I Silverberg, et al.
The British Journal of Dermatology|July 1, 2026
Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 yearElaine C Siegfried, Eulalia Baselga, Marlies de Graaf, et al.
Journal of the American Academy of Dermatology|March 6, 2020
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOSJonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, et al.
The Journal of Pediatrics|May 1, 2022
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional StudySebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, et al.
The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.
Allergy|July 11, 2022
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitisEvgeny Berdyshev, Elena Goleva, Robert Bissonnette, et al.
Journal of Drugs in Dermatology : JDD|August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 TrialsAndrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 10, 2000
Retroviral delivery of peptide modulators of cellular functionsJ B Lorens, M K Bennett, D M Pearsall, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 9, 2020
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, et al.
Pageof 73

Showing results (591-600 of 724) with videos related to

Sort By:
Pageof 73
Ecology and Evolution|July 25, 2018
Rivers shape population genetic structure in <i>Mauritia flexuosa</i> (Arecaceae)Nilo L Sander, Francisco Pérez-Zavala, Carolina J Da Silva, et al.
The British Journal of Dermatology|December 4, 2023
Burden of atopic dermatitis in paediatric patients: an international cross-sectional studyStephan Weidinger, Eric L Simpson, Jonathan I Silverberg, et al.
The British Journal of Dermatology|July 1, 2026
Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 yearElaine C Siegfried, Eulalia Baselga, Marlies de Graaf, et al.
Journal of the American Academy of Dermatology|March 6, 2020
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOSJonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, et al.
The Journal of Pediatrics|May 1, 2022
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional StudySebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, et al.
The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.
Allergy|July 11, 2022
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitisEvgeny Berdyshev, Elena Goleva, Robert Bissonnette, et al.
Journal of Drugs in Dermatology : JDD|August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 TrialsAndrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 10, 2000
Retroviral delivery of peptide modulators of cellular functionsJ B Lorens, M K Bennett, D M Pearsall, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 9, 2020
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, et al.
Pageof 73